We're saying goodbye to X and saying hello to bluer skies! Follow us on Bluesky at @bonumtx.com and on LinkedIn to stay connected and hear about our latest updates.

The Bonum team had a fantastic time sharing some of our work and connecting with old friends and new at #SITC24. Thanks to everyone @sitcancer for putting on such a great meeting. Looking forward to next year!

With growth comes change & the need for more space! Bonum has moved to 1150 Eastlake. Thanks to AAHI for housing us during our formative years & to our BOD—shown with CEO John Mulligan—for their guidance during this exciting transition. More at @PSBJ: bizj.us/1qlsd2

Happy second anniversary, Bonum! No 'terrible twos' here. Having cut our teeth as Good Therapeutics, we're up and running with our lead candidate, cLAG3-IL2, now in preclinical development. Thank you Team Bonum, and cheers to many more years of great discovery! 🥂

👀 in the #PNW: CSO Diane Hollenbaugh repping the oncology research community & the collective good they do! As National Cancer Research Month ends, Bonum recognizes the tireless efforts & enduring optimism of those working to create a better future. #NCRM2024 #ScienceSelfie

Heading to the Keystone Symposia’s “Antibodies as Drugs: The Art in Antibody Engineering” conference, May 5-8? Don’t miss your chance to learn about Bonum’s technology to generate conditionally activated protein therapeutics, & our lead asset, cLAG3-IL2: ow.ly/WqnT50RqQGG

Inspiring science? Check ✅ Fueling progress? Check ✅ Revolutionizing care? Check ✅ Bonum enjoyed sharing data on our lead candidate & and learning about the latest advances in cancer science & medicine at #AACR24! Next Up: #KSAntibodyEng24 in Breckenridge, CO, May 5-8, 2024

We were delighted to present our poster at #AACR24 this morning! Missed us? Take a closer look at the preclinical data on our lead program, cLAG3-IL2, demonstrating the power of Bonum's technology platform: bonumtx.com/wp-content/uploa…

Heading to #AACR24? Bonum will be sharing preclinical data for the first time on our lead program, cLAG3-IL2, demonstrating the power of our technology platform. Don't miss our poster on April 9th! For more info ⬇️ businesswire.com/news/home/2…

Bonum is focused on a proven technology that utilizes regulation to create targeted, highly active & less toxic medicines. Connect with John Mulligan, Diane Hollenbaugh, Justin Killebrew & Shannon Okada at #AACR24 as they share preclinical data on cLAG3-IL2.

Meeting investors', buyers', and sellers' goals isn't easy. Bonum's CBO Neela Patel offers advice on how to negotiate a winning deal that leaves all parties positioned for success in the Spring 2024 Issue of @DDWJournal, starting on page 62: ddw-online.com/ddw-spring-20…

Heading to #AACR24? Don't miss Bonum's presentation of pre-clinical data on our lead program, cLAG3-IL2. For more on our powerful technology platform, check out The Bio Report podcast w/ Bonum's Diane Hollenbaugh & Neela Patel. Listen now: ow.ly/3zgR50QVUzH @dslevine

TODAY: Don't miss Bonum's CBO Neela Patel at the Fierce BD&L Summit for Life Sciences 2024 as part of the “Creative Deal Structures for Traditional Asset Based Deals" panel discussion from 1:15-2:00pm PDT. For more info: bdlsummit.com/ #FierceBiotech #FiercePharma

Bonum's CBO Neela Patel will be at Fierce BD&L Summit for Life Sciences 2024 as part of the “Creative Deal Structures for Traditional Asset Based Deals" panel at 1:15pm PDT on Monday, March 11. More info & registration: bdlsummit.com/bdlsummitcom/2… #FierceBiotech #FiercePharma

Bonum will be sharing preclinical data for the first time at #AACR24 on our lead program, cLAG3-IL2, demonstrating the power of our technology platform. Don't miss our poster on April 9th! For more info ⬇️ businesswire.com/news/home/2…

At Bonum, we believe that treatment should be accessible to all & every patient deserves a chance for hope. On #WorldCancerDay, we applaud those who work to #CloseTheCareGap. Learn more about the campaign to create more equitable access to cancer services. worldcancerday.org

We're honored to be included in BioSpace's 'NextGen Class of 2024.' Bonum is excited to head into this new year with a talented team & a robust portfolio of pre-clinical assets based on a validated platform. ow.ly/1k1L50QnYTg

Bonum Therapeutics would like to thank all who contributed to our successes in 2023. We look forward to exciting things to come in 2024!

Founder & CEO @JohnMulligan42 & Chief Business Officer Neela Patel had a fantastic time discussing all things Bonum with @mattpillar on this week's #BusinessOfBiotech podcast. Thanks for a great conversation, Matt! bioprocessonline.com/doc/il-…

Can biotechs thrive when the market’s against them? “Yes,” says Founder & CEO, @JohnMulligan42, who shares tips on doing important science and running a successful biotech business in less-than-ideal market conditions w/ @PharmaVoice's Michael Gibney. pharmavoice.com/news/biotech…